Foscenvivint

N/A

Report date: 2022/10/23 13:37:56
NME

Base Information

Drug NameFoscenvivint
Drug Alias NamePRI-724ICG-001OP-724
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActioncAMP-response element binding protein inhibitorsCatenin beta 1 inhibitorsWnt signalling pathway inhibitors
TargetscAMP-response element binding proteinCatenin beta 1
Therapy Area/IndicationsSolid tumoursLiver CirrhosisLiver Cirrhosis, Biliary +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrism Pharma Co LtdUniversity Of Southern California
China Registration ClassN/A

Develop Information

Active CompaniesPrism Pharma Co LtdEisai Co LtdOhara Pharmaceutical Co Ltd
Inactive CompaniesUniversity Of Southern California
Active IndicationsLiver CirrhosisLiver Cirrhosis, BiliaryHepatitis C +[4] 
Inactive IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A